- Home
- ACB vs ZNTL Comparison
ACB vs ZNTL Comparison
Compare ACB & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACB
- ZNTL
- Stock Information
- Founded
- ACB 2013
- ZNTL 2014
- Country
- ACB Canada
- ZNTL United States
- Employees
- ACB N/A
- ZNTL N/A
- Industry
- ACB Pharmaceuticals and Biotechnology
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- ACB Health Care
- ZNTL Health Care
- Exchange
- ACB Nasdaq
- ZNTL Nasdaq
- Market Cap
- ACB 255.7M
- ZNTL 273.1M
- IPO Year
- ACB N/A
- ZNTL 2020
- Fundamental
- Price
- ACB $4.20
- ZNTL $3.47
- Analyst Decision
- ACB Hold
- ZNTL Buy
- Analyst Count
- ACB 1
- ZNTL 8
- Target Price
- ACB N/A
- ZNTL $10.50
- AVG Volume (30 Days)
- ACB 1.5M
- ZNTL 1.6M
- Earning Date
- ACB 11-06-2024
- ZNTL 11-12-2024
- Dividend Yield
- ACB N/A
- ZNTL N/A
- EPS Growth
- ACB N/A
- ZNTL N/A
- EPS
- ACB N/A
- ZNTL N/A
- Revenue
- ACB $219,835,671.00
- ZNTL $40,560,000.00
- Revenue This Year
- ACB $14.04
- ZNTL N/A
- Revenue Next Year
- ACB $8.94
- ZNTL N/A
- P/E Ratio
- ACB N/A
- ZNTL N/A
- Revenue Growth
- ACB 13.15
- ZNTL N/A
- 52 Week Low
- ACB $2.84
- ZNTL $2.66
- 52 Week High
- ACB $9.35
- ZNTL $18.07
- Technical
- Relative Strength Index (RSI)
- ACB 29.02
- ZNTL 49.60
- Support Level
- ACB $4.69
- ZNTL $3.65
- Resistance Level
- ACB $5.01
- ZNTL $4.44
- Average True Range (ATR)
- ACB 0.36
- ZNTL 0.42
- MACD
- ACB -0.15
- ZNTL 0.04
- Stochastic Oscillator
- ACB 1.88
- ZNTL 45.51
About ACB Aurora Cannabis Inc.
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.